Venn Life Sciences finds 'model client' in Carrick Therapeutics
18th Jan 2019 08:19
(Sharecast News) - Integrated drug development company Venn Life Sciences announced a partnership with Carrick Therapeutics on Friday.
Read moreVenn Life Sciences shuffles board, partners with Open Orphan DAC
11th Dec 2018 14:40
(Sharecast News) - Integrated drug development company Venn Life Sciences announced a strategic collaboration with Open Orphan DAC, as well as the issue of £1m in privately-held loan notes on Tuesday, to fund an increased focus of the business into the high growth area of orphan diseases.
Read moreVenn Life Sciences completes £4.74m Innovenn sale
18th Nov 2016 09:38
(ShareCast News) - Drug trial company Venn Life Sciences has completed the sale of its stake in Innovenn UK innovation unit to Integumen for up to £4.74m that will see it retain a majority stake as the newly created skin science company looks to float on AIM. Integumen has been set up by Venn's dire
Read moreVenn Life Sciences wins new contract worth EUR2.5m
8th Nov 2016 09:31
(ShareCast News) - Venn Life Sciences has signed a new contract worth €2.5m with Sedana Medical for a phase III trial. The trial, which is confined to patients in Germany and commences immediately, will confirm the efficacy and safety of sedation with isoflurane in ventilated intensive care patients
Read moreDirector dealings: Venn Life Sciences chairman sees value
2nd Nov 2016 16:13
(ShareCast News) - Venn Life Sciences chairman Allan Wood bought £50,000 worth of the contract clinical research provider's shares, it was revealed on Wednesday. Wood picked up 230,000 shares in two purchases at an average price of 21.67p. Shares in the AIM-listed company have drifted since interim
Read moreVenn Life Sciences shareholders approve sale of Innovenn UK
27th Oct 2016 14:26
(ShareCast News) - Drug development and clinical trial management contract research organisation Venn Life Sciences confirmed on Thursday that its shareholders had approved of a deal to offload Innovenn UK. The AIM-traded company had announced on 4 October that its wholly owned subsidiary, Venn Life
Read moreVenn Life Sciences to offload Innovenn UK
4th Oct 2016 14:33
(ShareCast News) - Contract research organisation Venn Life Sciences announced on Tuesday that its wholly owned subsidiary, Venn Life Sciences Limited, has entered into a conditional agreement under which it and Lynchwood Nominees Limited, as custodian for the Helium Rising Stars Fund, would sell th
Read moreVenn Life Sciences shares drop despite revenue rise
28th Sep 2016 11:21
(ShareCast News) - Drug development services and clinical trial management provider Venn Life Sciences announced its unaudited interim results for the six months to 30 June on Wednesday, with revenue of €9.06m, up from €4.25m in the first half of last year. The AIM-traded firm had EBITDA profit of €
Read moreVenn Life Sciences wins €2.8m contract
3rd Aug 2016 14:07
(ShareCast News) - Contract research organisation Venn Life Sciences said it has signed a new contract worth €2.8m with an unnamed European biotechnology client. Venn, which provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical dev
Read moreVenn Life Sciences expecting revenues to double
8th Jan 2016 16:44
(ShareCast News) - Venn Life Sciences was working to please investors on Friday, revealing its expectations for the year ahead of its full-year results. The AIM-listed drug development services company said revenues for the full year to 31 December were expected to be at least double the previous ye
Read moreVenn Life Sciences signs EUR1m contract
23rd Oct 2015 08:17
(ShareCast News) - Venn Life Sciences has signed a €1m contract with a leading French biotech company. The AIM listed clinical research organisation announced the deal on Friday. The two-phase project is centred on acute T-cell leukaemia, and will cover multiple regions including France, the UK and
Read moreVenn Life posts narrow interim loss, acquires Kinesis
22nd Sep 2015 15:51
(ShareCast News) - Clinical trial services provider Venn Life Sciences posted a narrower interim pre-tax loss and has agreed to acquire Kinesis Pharma BV. In the six months to the end of June, the London-listed company saw its pre-tax loss narrow from €987,000 (£716,000) to €259,000, while revenue a
Read moreVenn Life Sciences reports strong first-half trading
13th Aug 2015 11:35
(ShareCast News) - Venn Life sciences said it has had a strong first half, with revenues up 170% on the previous year. In a very brief trading update, the company, which provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, reported
Read moreVenn Life Sciences appoints new CFO
15th Jun 2015 10:13
Clinical research and development group Venn Life Sciences Holdings has confirmed Jonathan Hartshorn has begun his tenure as the group's new chief financial officer. The London-listed company had appointed Hartshorn, who left his role as head of finance for the onshore division of Mainstream Renewab
Read moreVenn Life Sciences acquires Cardinal Systems
5th Aug 2014 17:34
Venn Life Sciences, a clinical research organisation (CRO), announced on Tuesday the acquisition of Cardinal Systems SAS, a French CRO specialising in Data Management. The acquisition will allow Venn to extend its service of clinical trial management and resourcing solutions. The company will by
Read more